Hansa Biopharma Gets up to 350M to Make Gene Therapy Work in Resistant… – Labiotech.eu

Hansa Biopharma has granted an exclusive license to Sarepta Therapeutics for developing and promoting a pretreatment aimed to make a gene therapy to treat muscular dystrophy available to people that are naturally resistant to the treatment.

Gene therapy can be used to treat genetic conditions by delivering a healthy copy of the faulty gene using harmless recombinant viruses. The adeno-associated virus (AAV) is one of the most commonly used in gene therapy, and the basis of Sarepta Therapeutics gene therapy technology.

However, up to 70% of people naturally carry neutralizing antibodies against AAV. This prevents the transfer of the healthy gene sequence and raises safety concerns for the patient. Swedish company Hansa Biopharma is developing a pretreatment called imlifidase that works to eliminate these neutralizing antibodies prior to gene therapy treatments.

Imlifidase is an enzyme from the bacterium Streptococcus pyogenes that breaks down the antibodies that are involved in generating an immune response against external pathogens, inhibiting their activity within hours after administration.

Imlifidase is completely unique in development, said Emanuel Bjorne, VP Business Development at Hansa Biopharma. There is no product in the market that has this mode of action.

Sarepta Therapeutics aims to use imlifidase to extend its gene therapies for Duchenne muscular dystrophy and Limb-girdle muscular dystrophy to those patients that are naturally resistant to the AAV vectors used to deliver these treatments. According to the agreement, Hansa will get 8.8M ($10M) upfront and is eligible for a total of 350M ($397M) in development, regulatory, and sales milestone payments, in addition to royalties to future sales.

Sarepta Therapeutics will conduct preclinical evaluation of imlifidase as a pretreatment for gene therapy with Hansa providing our imlifidase expertise to the collaboration, said Bjorne. If everything goes according to plan, the company will start a clinical study of imlifidase in combination with Sareptas gene therapy in the second half of next year.

In preclinical models, Hansas technology has been successful in clearing the antibodies that prevent the success of gene therapies. If successful, this could offer the potential of extending existing gene therapy treatments to patients who would otherwise not be able to benefit from them. Hansa Biopharma is also investigating the use of this drug as a way to prevent the rejection of transplanted organs, and to treat cancer and rare autoimmune conditions.

Antara Mazumdar is a computational biologist based in Groningen, The Netherlands. She is also a freelance science writer who writes about various areas of biological research. Prior to that, she studied biomedical science and bioinformatics in New Delhi, India. Outside of work, she enjoys organizing scientific and cultural events, singing and is a traveling enthusiast.

View original post here:

Hansa Biopharma Gets up to 350M to Make Gene Therapy Work in Resistant... - Labiotech.eu

Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress – GlobeNewswire

All five participants in the 5x1011 vg/kg and 11012 vg/kg dose cohorts and seven participants in the 21012 vg/kg dose show an acceptable safety profile, stable and durable factor VIII expression and substantial improvement in annualized bleed rate (ABR) after between two and 3.3 years follow-up

Represents the longest stable expression of FVIII following investigational gene therapy and reinforces the ability of AAV gene therapy targeting hepatocytes to achieve stable and durable FVIII expression

Optimizing the dose and immunomodulatory regimen; Phase 3 dosing expected in 2021

PHILADELPHIA, July 12, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced updated data from three dose cohorts of the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A. These data were presented at the International Society of Thrombosis and Hemostasis (ISTH) 2020 Virtual Congress by Principal Investigator Lindsey A. George, M.D., The Perelman School of Medicine, University of Pennsylvania and Childrens Hospital of Philadelphia.

Fourteen participants in the Phase 1/2 trial received a single administration of investigational SPK-8011, two at a dose of 5x1011 vg/kg, three at a dose of 11012 vg/kg and nine at a dose of 21012 vg/kg. As of the June 3, 2020 data cutoff, results from the five total participants in the 5x1011 vg/kg and 11012 dose cohorts and seven participants in the 21012 vg/kg dose cohort show an acceptable safety profile, 91-percent reduction in annualized bleed rate (ABR), 96-percent reduction in FVIII infusions and stable and durable factor FVIII expression after between two and 3.3 years of follow-up.

As previously disclosed, two of nine participants in the 21012 dose cohort lost FVIII expression likely due to a capsid-based immune response. The seven other participants in the 21012 dose cohort and the five total participants in the 51011 vg/kg and 11012 vg/kg dose cohorts continue to show stable and durable factor FVIII expression. These data represent the longest stable expression of FVIII following investigational gene therapy and reinforce the ability of AAV gene therapy targeting hepatocytes to achieve stable and durable FVIII expression.

We are very encouraged by these interim data that continue to show an acceptable safety profile and a substantial reduction in bleeds for more than two years of observation on average, with one participant being observed for more than three years, said Federico Mingozzi, Ph.D., chief scientific officer, Spark Therapeutics. Our focus is on optimizing the dose and immunomodulatory regimen before moving to a Phase 3 clinical study that falls in line with our strategy to progress a hemophilia A gene therapy that, at thelowest effective doseand the optimal immunomodulatory regimen, demonstrates safety, predictability, efficacy, and durability.

Since previous disclosure of these data, two participants experienced mild and non-serious steroid-associated adverse events (e.g. weight gain, insomnia, adrenal insufficiency and worsening gastroesophageal reflux that resolved with medical intervention). Previously disclosed adverse events include one participant experiencing an acute reaction to the infusion that resolved. Three participants reported liver function test (LFT) elevations. One of the events was grade two transaminitis, and two were grade one. All three events resolved. One participant was electively admitted to the hospital to receive intravenous steroids. The event subsequently resolved. The admission to the hospital for these infusions met the criteria for a serious adverse event.

Across the Phase 1/2 study and through the data cutoff, all 14 participants demonstrated rapid clearance of vector from semen, serum, saliva and urine within two weeks post-vector administration. The vector was not detectable in peripheral blood mononuclear cells (PBMCs), semen, serum, saliva and urine by six weeks post-vector administration in all participants.

Spark Therapeutics continues optimizing the dose and immunomodulatory regimen for investigational SPK-8011 and SPK-8016, for hemophilia A patients with inhibitors. The Phase 3 run-in study is ongoing, and dosing participants in Phase 3 is expected to occur in 2021.

Additionally, Spark has scaled-up its state-of-the-art gene therapy manufacturing capabilitiesutilizing suspension cell culture at a scale of nearly 500-litersatcell separationwith a corresponding chromatography purification process, which is the scale required to meet clinical and potential commercial demand for hemophilia A.

About SPK-8011 for hemophilia AInvestigationalSPK-8011, a novel bio-engineered adeno-associated viral (AAV) vector utilizing the AAV-LK03 capsid, also referred to as Spark200, contains a codon-optimized human factor VIII gene under the control of a liver-specific promoter. The Food and Drug Administration (FDA) granted orphan-disease designation and breakthrough therapy designation in the U.S., while the European Commission has granted orphan designation toSPK-8011.

About Roche and Spark Therapeutics gene therapy research in hemophilia AWe believe gene therapy has the potential to revolutionize medicine and improve the lives of patients with genetic and other serious diseases. Pairing Roches long-standing commitment to developing medicines in hemophilia with Spark Therapeutics proven gene therapy expertise brings together the best team of collaborators researching gene therapies in hemophilia A.

It is our aligned objective to develop gene therapies for hemophilia A that, with the lowest effective dose and the optimal immunomodulatory regimen, demonstrate safety, predictability, efficacy, and durability for patients.

About Hemophilia AHemophilia is a rare genetic bleeding disorder that causes the blood to take a long time to clot because of a deficiency in one of several blood clotting factors. People living with hemophilia are at risk of excessive and recurrent bleeding spontaneously and from modest injuries, which have the potential to be life threatening. There are approximately 15,000 people with hemophilia A in the U.S. and 19,000 in the five major European countries. Hemophilia A is about four times as common as hemophilia B. Hemophilia A is characterized by mutations in the factor VIII gene (F8), which lead to deficient blood coagulation and an increased risk of bleeding or hemorrhaging. The current standard of care for hemophilia A requires recurrent intravenous infusions of either plasma-derived or recombinant factor VIII to control and prevent bleeding episodes. There exists a significant need for novel therapeutics to treat people living with hemophilia.

About Spark Therapeutics AtSpark Therapeutics, a fully integrated, commercial company committed to discovering, developing and delivering gene therapies, we challengethe inevitability of genetic diseases,includingblindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.We currently have four programs in clinical trials.At Spark, a member of the Roche Group, we see the path to a world where no life is limited by genetic disease. For more information, visit http://www.sparktx.com, and follow us on Twitter and LinkedIn.

Media Contact:Kevin Giordanokevin.giordano@sparktx.com(215) 294-9942

Visit link:

Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress - GlobeNewswire

Gene Therapy- Global Market Set to Register the Highest Economic Growth by 2025 – 3rd Watch News

Market Research Exploreoffers an exhaustive analysis on the Global Gene Therapy Market covering diverse significant factors that pose an impact on the current and forthcoming market conditions. The report elaborates on how the Gene Therapy market has been performing over the last five years at the global and regional levels. It also analyzes expected ups and downs in the market over the next five years. The report assists market players to operate their business wisely. Market scope, establishment, profitability, maturity, and growth prospects are also highlighted in the global Gene Therapy market report.

The report mainly emphasizes the market rivalry landscape, leading players profiles, segmentation, and industry environments which have been playing an integral role in posing impacts on market structure and profitability. It also includes a precise assessment of market share, size, demand, production, sales, and revenue that help intuit the financial health of the industry. It also illuminates various market dynamics such as changing product values, demand-supply variations, contemporary trends, pricing fluctuations, growth-driving forces, and unstable market conditions.

Sample Copy Global Gene Therapy Market Report 2020:https://www.marketresearchexplore.com/report/global-gene-therapy-industry-market-research-report/174122#enquiry

Extensive study of crucial Gene Therapy market segments:

The global Gene Therapy market has been segmented into a number of various vital segments such as types, applications, and regions. The report evaluates each segment at a minute level in view of its growth prospects, global demand, and current revenue. It also focuses on the segments that are exhibiting exponential growth during the year and help market players in selecting more profitable segments for their Gene Therapy businesses and precisely determine the actual needs and wants of their customer base.

Global Gene Therapy Market Competitive Assessment:

Expansive survey of Global Gene Therapy Market 2020

According to the report findings, the global Gene Therapy market report is extremely competitive and encouraging leading manufacturers and companies to execute various business and marketing strategies such as M&A activities, brand promotions, product launches, partnerships, and other expansions to perform comfortably in the relentless competition. The report further examines highlights new product developments, innovations, and technology adoptions done by the competitors in order to offer upgraded products and services in the global Gene Therapy market.

The report also provides a detailed financial assessment of leading market vendors and insights into the competencies and capacities of these companies to assist Gene Therapy market players for business expansions. The report also deeply analyzes effective product lines offered by various manufacturers and helps other participants to boost the quality of their products. Analysis based on forthcoming challenges and opportunities is also highlighted in the report, which will help Gene Therapy market players build lucrative strategies and grab all growth opportunities.

Significant Features of the Global Gene Therapy Market Report:

Connect with our industry experts at[emailprotected].

See more here:

Gene Therapy- Global Market Set to Register the Highest Economic Growth by 2025 - 3rd Watch News

CNS Gene Therapy Market is Anticipated to Attain a Market Value of US$XX by the End of 2018 2028 – 3rd Watch News

The global CNS Gene Therapy market gives detailed Evaluation about all of the Important aspects related to the market. The study on international CNS Gene Therapy economy, offers deep insights regarding the CNS Gene Therapy market covering all of the crucial aspects of the marketplace. Moreover, the report provides historical information with prospective forecast over the forecast period. Various important factors like market trends, revenue growth patterns market stocks and supply and demand are contained in almost all the market research document for every business. A number of the important aspects analysed in the report contains market share, creation, key regions, revenue rate as well as key players.

The study of various sections of the international market are also Covered in the research report. In addition to that, for the forecast periods conclusion of factors such as market size and the competitive landscape of the market is analysed in the report. Due to the rising globalization and digitization, there are new trends coming to the marketplace daily. The research report provides the detailed analysis of all of these tendencies.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/27514

In addition, the CNS Gene Therapy marketplace report also supplies the Latest trends in the global CNS Gene Therapy market with the assistance of primary in addition to secondary research methodologies. Also, the analysis report on CNS Gene Therapy market gives a wide analysis of the market including market overview, production, manufacturers, dimensions, price, value, growth rate, income, prices, export, consumption, and sales revenue of this global CNS Gene Therapy market. On the other hand, the CNS Gene Therapy market report also studies the market status for the prediction period. However, this will help to grow the advertising opportunities throughout the world as well as major market suppliers.

key players and product offerings

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/27514

The CNS Gene Therapy market report provides helpful insights for Every established and innovative players throughout the globe. Additionally the CNS Gene Therapy market report provides accurate evaluation for the shifting competitive dynamics. This study report includes a complete analysis of future growth in terms of the evaluation of the mentioned forecast period. The CNS Gene Therapy market report offers a comprehensive analysis of the technological advancement prognosis over time to be aware of the market growth prices. The CNS Gene Therapy market report also has progressive analysis of the huge number of unique facets which are boosting or operating in addition to regulating the CNS Gene Therapy market growth.

A systematized methodology can be utilized to create a Report on the Global CNS Gene Therapy market. For the research of economy on the Conditions of study Approaches, these techniques are useful. All of the Information Regarding this Products, makers, vendors, clients and much more is covered in research reports. Various important factors like market trends, revenue Growth patterns market stocks and demand and supply are included in virtually all The market study report for every industry. Adaptation of fresh ideas and Accepting the most recent trends are a few the reasons for virtually any markets growth. The Global CNS Gene Therapy market research report provides the profound understanding about the Regions in which the marketplace is impactful.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/27514

Read more:

CNS Gene Therapy Market is Anticipated to Attain a Market Value of US$XX by the End of 2018 2028 - 3rd Watch News

Carmine Therapeutics teams up with Takeda for non-viral gene therapies – BSA bureau

Carmine Therapeutics and Takeda Collaborate to Discover and Develop Rare Disease Gene Therapies Using Novel Red Blood Cell Extracellular Vesicles Platform

Singapore based startup Carmine Therapeutics has announced that it has signed a research collaboration agreement with Japanese firm Takeda Pharmaceutical Company Limited o discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmines REGENT(TM) technology, based on red blood cell extracellular vesicles. In addition, Takeda has committed a $5M convertible loan in support of the development of Carmines novel REGENT platform.

Under the terms of the agreement, Carmine will receive an upfront payment, research funding support, and is eligible for over $900M in total milestone payments plus tiered royalties.

Takeda has an option to license the programs following the completion of pre-clinical proof of concept studies and would be responsible for clinical development and commercialization.

Carmine Therapeutics is pioneering a novel class of therapeutics based on its REGENT(TM) technology which leverages red blood cell extracellular vesicles (RBCEVs), first published in Nature Communications in 2018.

An initial focus is non-viral gene therapies. Compared to adeno-associated virus (AAV)-based gene therapy, RBCEV-based gene therapy has the potential for repeat dosing, a significantly larger transgene payload capacity in excess of 11KB, and enhanced bio-distribution in selected tissues through RBCEV surface modification.

Read more here:

Carmine Therapeutics teams up with Takeda for non-viral gene therapies - BSA bureau

Gene Therapy Market Size By Types, By Application, By Region, And Forecast 20202027 – Owned

New Jersey, United States,- The Gene Therapy Market report upholds the future market predictions related to Gene Therapy market size, revenue, production, Consumption, gross margin, and other substantial factors. It also examines the role of the prominent Gene Therapy market players involved in the industry including their corporate overview. While emphasizing the key driving factors for the Gene Therapy market, the report also offers a full study of the future trends and developments of the market.

The recently documented report on the Gene Therapy market is a detailed analysis of this business landscape and contains important details regarding the present market trends, current revenue, market size, industry share, periodic deliverables, alongside the profit anticipation and growth rate registered during the estimated timeframe.

A thorough inference pertaining to the performance of the Gene Therapy market over the forecast period, along with the key factors driving the market growth is enclosed in the report. It also delivers information about the market dynamics and focusses on the challenges encountered by the business vertical while providing a brief about the growth opportunities prevailing in the market over the analysis timeline.

Key highlights of the Gene Therapy market report:

The essence of the regional bifurcation of the business sphere presented in the report:

Top key players of industry are covered in Gene Therapy Market Research Report:

Gene Therapy Market Classification by Types:

Bytype1

Gene Therapy Market Size by End-user Application:

Byapplication1

Additional insights about the competitive landscape of the Gene Therapy market:

Factors defining the competitive landscape included in the report are:

The Gene Therapy market report encompasses a comprehensive analysis of the key facets including market concentration ratio.

The objective of the Gene Therapy Market Report:

Cataloging the competitive terrain of the Gene Therapy market:

Unveiling the geographical penetration of the Gene Therapy market:

The report of the Gene Therapy market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Gene Therapy Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Gene Therapy Market report

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Furniture Logistics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Outsourced Semiconductor Assembly And Test (OSAT) Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Pine Pollen Powder Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

HVAC Equipment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Data Governance Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original here:

Gene Therapy Market Size By Types, By Application, By Region, And Forecast 20202027 - Owned

British biotech Freeline secures 106 million for its curative liver gene therapies – EU-Startups

UK-based Freeline, a biotechnology startup focused on developing curative gene therapies for chronic systemic diseases, has announced the closing ofan around 106 million extended Series C financing. Thisround includes a previously announced 35.4 million from Syncona, in addition to a more recentadditional amount of around 70.8 million led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.

Freeline, founded in 2015, aims to create better lives for people suffering from chronic, debilitating diseases. Combining innovation with an entrepreneurial spirit, they aim for life-changing impact by developing and commercialising innovative gene therapies. At the centre of their work is the goal to create functional cures for a wide range of liver-based diseases, which have previously been underserved and incurable.

The Stevenage-based biotech startup will use the funds to bring its lead programme in Haemophilia B into a pivotal trial, as well as to continue its Phase 1/2 clinical programme for Fabry Disease and further progress its pipeline programmes for Gaucher Disease and Haemophilia A. Additionally, Freeline expects to use the proceeds from the financing to further develop its proprietary gene therapy platform using next-generation AAV technology and expand its manufacturing capabilities.

The potential of gene therapy to change patients lives has never been greater and we are delighted to have leading US and European biotechnology investors join us in this extended Series C financing, said Theresa Heggie, CEO of Freeline. It comes at an exciting time for Freeline with our lead programme in Haemophilia B progressing through clinical development, and with promising programmes behind that, including a gene therapy treatment for Fabry Disease in the clinic and for Gaucher Disease and Haemophilia A in late preclinical development.

Our investment strategy is to identify and invest in US and European life science companies which are true leaders in their area of expertise, developing innovative product candidates that significantly advance patient care, said Thomas Dyrberg, Managing Partner, Novo Ventures, Novo Holdings A/S. We have been impressed by the Freeline platform and its scientific co-founders, as well as their experienced management team, and we are delighted to support Freeline as they continue to build momentum.

In connection with the financing, Freeline will appoint Thomas Dyrberg of Novo Holdings A/S to its Board of Directors.

Read the original post:

British biotech Freeline secures 106 million for its curative liver gene therapies - EU-Startups

Gene Therapy For CNS Disorders Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To…

New Jersey, United States,- Latest update on Gene Therapy For CNS Disorders Market Analysis report published with extensive market research, Gene Therapy For CNS Disorders Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Gene Therapy For CNS Disorders industry. With the classified Gene Therapy For CNS Disorders market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Gene Therapy For CNS Disorders market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Gene Therapy For CNS Disorders market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Gene Therapy For CNS Disorders Market growth opportunities in the industry.

Gene Therapy For CNS Disorders Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Gene Therapy For CNS Disorders market size, volume and value, as well as price data.

Gene Therapy For CNS Disorders Market competition by top Manufacturers:

Gene Therapy For CNS Disorders Market Classification by Types:

Gene Therapy For CNS Disorders Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Gene Therapy For CNS Disorders Market Report:

Cataloging the competitive terrain of the Gene Therapy For CNS Disorders market:

Unveiling the geographical penetration of the Gene Therapy For CNS Disorders market:

The report of the Gene Therapy For CNS Disorders market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Gene Therapy For CNS Disorders Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Gene Therapy For CNS Disorders Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read more:

Gene Therapy For CNS Disorders Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To...

Retinal Gene Therapy Market Set to Surpass US$XX Million by the end of 2019 2029 – 3rd Watch News

The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Retinal Gene Therapy market. It sheds light on how the global Retinal Gene Therapy market is expected to grow during the course of the forecast period. With SWOT analysis and Porters Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global Retinal Gene Therapy market and different players operating therein. The authors of the report have also provided qualitative and quantitative analyses of several microeconomic and macroeconomic factors impacting the global Retinal Gene Therapy market. In addition, the research study helps to understand the changes in the industry supply chain, manufacturing process and cost, sales scenarios, and dynamics of the global Retinal Gene Therapy market.

Each player studied in the report is profiled while taking into account its production, market value, sales, gross margin, market share, recent developments, and marketing and business strategies. Besides giving a broad study of the drivers, restraints, trends, and opportunities of the global Retinal Gene Therapy market, the report offers an individual, detailed analysis of important regions such as North America, Europe, and Asia Pacific. Furthermore, important segments of the global Retinal Gene Therapy market are studied in great detail with key focus on their market share, CAGR, and other vital factors.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-10246

Regional Wise Outlook

Geographically, the retinal gene therapy market is segmented into seven regions viz. South Asia, East Asia, North America, Latin America, Oceania, Europe, and Middle East and Africa. The North America retinal gene therapy market is the leader in the concerned global retinal gene therapy market. The only product approved is from a US based manufacturer, which reflects to the current market share for North America. The retinal gene therapy is also available in Europe from Spark Therapeutics. The deal is such that Novartis has exclusive rights to commercialize and distribute Luxturna in Europe and in all other countries outside the US, when regularized for use. So, clearly the current market for retinal gene therapy is consolidated in these two region.

The only player involved in this market of retinal gene therapy is Spark Therapeutics, Inc. The present market structure of retinal gene therapy is expected to change with efforts and research present in clinical phase.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.

The report also maps the qualitative impact of various market factors on market segments and geographies.

Regional analysis of the Retinal Gene Therapy market report includes

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-10246

Table of Contents Covered In Retinal Gene Therapy Market Are:

Industry Overview: The first section of the research study touches on an overview of the global Retinal Gene Therapy market, market status and outlook, and product scope. Additionally, it provides highlights of key segments of the global Retinal Gene Therapy market, i.e. regional, type, and application segments.

Competition Analysis: Here, the report brings to light important mergers and acquisitions, business expansions, product or service differences, market concentration rate, the competitive status of the global Retinal Gene Therapy market, and market size by player.

Company Profiles and Key Data: This section deals with the company profiling of leading players of the global Retinal Gene Therapy market on the basis of revenue, products, business, and other factors mentioned earlier.

Market Size by Type and Application: Besides offering a deep analysis of the size of the global Retinal Gene Therapy market by type and application, this section provides a study on top end users or consumers and potential applications.

North America Market: Here, the report explains the changes in the market size of North America by application and player.

Europe Market: This section of the report shows how the size of the Europe market will change in the next few years.

China Market: It gives analysis of the China market and its size for all the years of the forecast period.

Rest of Asia Pacific Market: The Rest of Asia Pacific market is analyzed in quite some detail here on the basis of application and player.

Central and South America Market: The report explains the changes in the size of the Central and South America market by player and application.

MEA Market: This section shows how the size of the MEA market will change during the course of the forecast period.

Market Dynamics: Here, the report deals with the drivers, restraints, challenges, trends, and opportunities of the global Retinal Gene Therapy market. This section also includes the Porters Five Forces analysis.

Research Findings and Conclusion: It gives powerful recommendations for new as well as established players for securing a position of strength in the global Retinal Gene Therapy market.

Methodology and Data Source: This section includes the authors list, a disclaimer, research approach, and data sources.

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-10246

Key Questions Answered in Retinal Gene Therapy Market Report are:

Research Methodology of Retinal Gene Therapy

Retinal Gene Therapy Market Report uses trustworthy primary and secondary research sources to compile its reports. It also relies on latest research techniques to prepare highly detailed and accurate research studies such as this one here. It uses data triangulation, top down and bottom up approaches, and advanced research processes to come out with comprehensive and industry-best market research reports.

See original here:

Retinal Gene Therapy Market Set to Surpass US$XX Million by the end of 2019 2029 - 3rd Watch News

Gene Therapy Market : Facts, Figures and Analytical Insights 2020 2029 – 3rd Watch News

The research study on Global Gene Therapy market 2019 presents an extensive analysis of current Gene Therapy market size, drivers, trends, opportunities, challenges, as well as key Gene Therapy market segments. Further, it explains various definitions and classification of the Gene Therapy industry, applications, and chain structure.In continuation of this data, the Gene Therapy report covers various marketing strategies followed by key players and distributors. Also explains Gene Therapy marketing channels, potential buyers and development history. The intent of global Gene Therapy research report is to depict the information to the user regarding Gene Therapy market forecast and dynamics for the upcoming years. The Gene Therapy study lists the essential elements which influence the growth of Gene Therapy industry. Long-term evaluation of the worldwide Gene Therapy market share from diverse countries and regions is roofed within the Gene Therapy report. Additionally, includes Gene Therapy type wise and application wise consumption figures.

The Final Report will cover the impact analysis of COVID-19 on this industry.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225591

After the basic information, the global Gene Therapy Market study sheds light on the Gene Therapy technological evolution, tie-ups, acquisition, innovative Gene Therapy business approach, new launches and Gene Therapy revenue. In addition, the Gene Therapy industry growth in distinct regions and Gene Therapy R;D status are enclosed within the report.The Gene Therapy study also incorporates new investment feasibility analysis of Gene Therapy. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Gene Therapy market.

Global Gene Therapy Market Segmentation 2019: Gene TherapyThe study also classifies the entire Gene Therapy market on basis of leading manufacturers, different types, various applications and diverse geographical regions. Overall Gene Therapy market is characterized by the existence of well-known global and regional Gene Therapy vendors. These established Gene Therapy players have huge essential resources and funds for Gene Therapy research as well as developmental activities. Also, the Gene Therapy manufacturers focusing on the development of new Gene Therapy technologies and feedstock. In fact, this will enhance the competitive scenario of the Gene Therapy industry.

The Leading Players involved in global Gene Therapy market are:

By Gene Therapy Type (Germline Gene Therapy and Somatic Gene Therapy)

By Type of Vector (Viral Vector and Non-viral Vector)

By Disease Indication (Cardio Vascular Diseases, Cancer, Genetic Disorders, Neuro Disorders, Infectious Diseases, and Others)

By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225591

Worldwide Gene Therapy Market Different Analysis:Competitors Review of Gene Therapy Market: Report presents the competitive landscape scenario seen among top Gene Therapy players, their company profile, revenue, sales, business tactics and forecast Gene Therapy industry situations. Production Review of Gene Therapy Market: It illustrates the production volume, capacity with respect to major Gene Therapy regions, application, type, and the price. Sales Margin and Revenue Accumulation Review of Gene Therapy Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Gene Therapy target consumer. Supply and Demand Review of Gene Therapy Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Gene Therapy product type. Also interprets the Gene Therapy import/export scenario. Other key reviews of Gene Therapy Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Gene Therapy players, potential consumers and suppliers. Also, the strengths, opportunities, Gene Therapy market driving forces and market restraints are studied in this report.

Highlights of Global Gene Therapy Market Report:* This report provides in detail analysis of the Gene Therapy and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 ; 2029. * It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Gene Therapy market. * This study also provides key insights about Gene Therapy market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Gene Therapy players. * It profiles leading players in the worldwide Gene Therapy market based on the following parameters ; company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans. * Insights from Gene Therapy report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Gene Therapy marketing tactics. * The world Gene Therapy industry report caters to various stakeholders in Gene Therapy market. That includes investors, device manufacturers, distributors and suppliers for Gene Therapy equipment. Especially incorporates government organizations, Gene Therapy research and consulting firms, new entrants, and financial analysts. *Various strategy matrices used in analyzing the Gene Therapy market would provide stakeholders vital inputs to make strategic decisions accordingly.

Global Gene Therapy Market Report Provides Comprehensive Analysis of Following: ; Gene Therapy Market segments and sub-segments ; Industry size ; Gene Therapy shares ; Gene Therapy Market trends and dynamics ; Market Drivers and Gene Therapy Opportunities ; Supply and demand of world Gene Therapy industry ; Technological inventions in Gene Therapy trade ; Gene Therapy Marketing Channel Development Trend ; Global Gene Therapy Industry Positioning ; Pricing and Brand Strategy ; Distributors/Traders List enclosed in Positioning Gene Therapy Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225591

Moreover, the report organizes to provide essential information on current and future Gene Therapy market movements, organizational needs and Gene Therapy industrial innovations. Additionally, the complete Gene Therapy report helps the new aspirants to inspect the forthcoming opportunities in the Gene Therapy industry. Investors will get a clear idea of the dominant Gene Therapy players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

Read more from the original source:

Gene Therapy Market : Facts, Figures and Analytical Insights 2020 2029 - 3rd Watch News

The Wilderness of Rare Genetic Diseases and the Parents Navigating It – The New York Times

A confirmed diagnosis may take time.

Diagnosis represents the first step on this rare disease journey. Sometimes doctors will notice something off about the child during a newborn screening, and a genetic test will identify a known mutation in the DNA. But not all conditions are so quickly detected, and it can take several years for parents to get a confirmed diagnosis.

About half of all children never get that far, according to Marshall Summar, M.D., the director of the Rare Disease Institute at Childrens National Hospital in Washington, D.C. When you sequence someones DNA, you are going to find a lot of changes, Dr. Summar said. Figuring out which change might be the one that is causing it is a tremendous challenge.

Genetic counselors warn parents beforehand that they may not get a definitive answer as to what condition their child could have. They may have to check back each year. Dr. Summar estimates that between five and 10 new rare diseases are described in the scientific literature every week, making it challenging for the medical field to keep up.

Meanwhile, the realization that a child may have a debilitating, lifelong condition weighs heavily. Some parents, particularly mothers, blame themselves, said Lemuel Pelentsov, Ph.D., a nurse who studies the needs of rare disease families at the University of South Australia, in Adelaide. In a 2016 study by Dr. Pelentsov and his colleagues, about 40 percent of the 300 rare parents surveyed reported being treated for depression and an equal number for anxiety. One of the things they do to combat that, he said, is get very invested in the childs disease.

When parents reach out to other parents, they are not simply looking for emotional support or advice. They are rebuilding a social life, one that will revolve around their childs disease. Many rare diseases have their own support groups. Global Genes is an umbrella group that supports 600 disease-specific foundations, as well as parents of children whose diseases are so rare they have no foundation.

We encourage folks to work together, said Kimberly Haugstad, the organizations executive director whose son has a rare form of hemophilia, a condition in which the blood doesnt clot normally. The parent is going to come from such different places in their own walk of life.

Each year, Global Genes hosts a Rare Boot Camp to mentor and teach parents how to set up a nonprofit, create patient registries and fund research. After attending the boot camp, the Van Wyks and other parents founded GACI Global, an organization that connects families affected by GACI, along with medical professionals.

Here is the original post:

The Wilderness of Rare Genetic Diseases and the Parents Navigating It - The New York Times

From floating guts to ‘sticky’ blood here’s how to do surgery in space – The Next Web

Earlier this year, it was reported that an astronaut in space had developed a potentially life-threatening blood clot in the neck. This was successfully treated with medication by doctors on Earth, avoiding surgery. But given that space agencies and private spaceflight companies have committed to landing humans on Mars in the coming decades, we may not be so lucky next time.

Surgical emergencies are in fact one of the main challenges when it comes to human space travel. But over the last few years, space medicine researchers have come up with a number of ideas that could help, from surgical robots to 3D printers.

Mars is a whopping 54.6 million kilometers (33.9 million miles) away from Earth, when closest. In comparison, the International Space Agency (ISS) orbits just 400 kilometers above Earth. For surgical emergencies on the ISS, the procedure is to stabilize the patient and transport them back to Earth, aided by telecommunication in real time. This wont work on Mars missions, where evacuation would take months or years, and there may be a latency in communications of over twenty minutes.

As well as distance, the extreme environment faced during transit to and on Mars includes microgravity, high radiation levels and an enclosed pressurized cabin or suit. This is tough on astronauts bodies and takes time getting used to.

We already know that space travel changes astronauts cells, blood pressure regulation and heart performance. It also affects the bodys fluid distribution and weakens its bones and muscles. Space travelers may also more easily develop infections. So in terms of fitness for surgery, an injured or unwell astronaut will be already at a physiological disadvantage.

Astronaut Chris Hadfield using a cardio lab at the ISS. NASA

But how likely is it that an astronaut will actually need surgery? For a crew of seven people, researchers estimate that there will be an average of one surgical emergency every 2.4 years during a Mars mission. The main causes include injury, appendicitis, gallbladder inflammation or cancer. Astronauts are screened extensively when they are selected, but surgical emergencies can occur in healthy people and may be exacerbated in the extreme environment of space.

Surgery in microgravity is possible and has already been been carried out, albeit not on humans yet. For example, astronauts have managed to repair rat tails and perform laroscopy a minimally invasive surgical procedure used to examine and repair the organs inside the abdomen on animals, while in microgravity.

These surgeries have led to new innovations and improvements such as magnetizing surgical tools so they stick to the table, and restraining the surgeonaut too.

One problem was that, during open surgery, the intestines would float around, obscuring view of the surgical field. To deal with this, space travelers should opt for minimally invasive surgical techniques, such as keyhole surgery, ideally occurring within patients internal cavities through small incisions using a camera and instruments.

A laroscopy was recently carried out on fake abdomens during a parabolic zero gravity flight, with surgeons successfully stemming traumatic bleeding. But they warned that it would be psychologically hard to carry out such a procedure on a crew mate.

Bodily fluids will also behave differently in space and on Mars. The blood in our veins may stick to instruments because of surface tension. Floating droplets may also form streams that could restrict the surgeons view, which is not ideal. The circulating air of an enclosed cabin may also be an infection risk. Surgical bubbles and blood-repelling surgical tools could be the solution.

Researchers have already developed and tested various surgical enclosures in microgravity environments. For example, NASA evaluated a closed system comprising a surgical clear plastic overhead canopy with arm ports, aiming to prevent contamination.

When orbiting or settled on Mars, however, we would ideally need a hypothetical traumapod, with radiation shielding, surgical robots, advanced life support and restraints. This would be a dedicated module with filtered air supply and a computer to aid in diagnosis and treatment.

The surgeries carried out in space so far have revealed that a large amount of support equipment is essential. This is a luxury the crew may not have on a virgin voyage to Mars. You cannot take much equipment on a rocket. It has therefore been suggested that a 3D printer could use materials from Mars itself to develop surgical tools.

Tools that have been 3D printed have been successfully tested by crew with no prior surgical experience, performing a task similar to surgery simply by cutting and suturing materials (rather than a body). There was no substantial difference in time to completion with 3D printed instruments such as towel clamps, scalpel handles and toothed forceps.

A Mars settlement would need a traumapod. NASA

Robotic surgery is another option that has been used routinely on Earth, and tested for planetary excursions. During NEEMO 7, a series of missions in the underwater habitat Aquarius in Florida Keys by NASA, surgery by a robot controlled from another lab was successfully used to remove a fake gallbladder and kidney stone from a fake body. However, the lag in communications in space will make remote control a problem. Ideally, surgical robots would need to be autonomous.

There is a wealth of research and preparation for the possible event of a surgical emergency during a Mars mission, but there are many unknowns, especially when it comes to diagnostics and anesthesia. Ultimately, prevention is better than surgery. So selecting healthy crew and developing the engineering solutions needed to protect them will be crucial.

This article is republished from The ConversationbyNina Louise Purvis, Postgraduate Researcher in Space Medicine, Kings College Londonunder a Creative Commons license. Read the original article.

Read next: Learn how to build a website the old-fashioned way with this HTML and CSS primer

Do you want to get the sassiest daily tech newsletter every day, in your inbox, for FREE? Of course you do: sign up for Big Spam here.

Go here to see the original:

From floating guts to 'sticky' blood here's how to do surgery in space - The Next Web

I worked for a decade at NASA and I can tell you the ‘Mars bros’ have it all wrong – The Independent

NASA is scheduled to launch another rover to Mars on July 20.

Yawn.

Sharing the full story, not just the headlines

During the decade I worked at NASA, my job involved touring the Space Shuttle trainer, exploring experimental extraterrestrial habitats, holding meteorites and donning a bunny suit for the clean room, where satellites were built. My friends nicknamed me The Astronaut.

Youd be perfect, they said, knowing I was athletic and daring in my role as senior science editor. Just fill out the astronaut application. I knew my oceanography background qualified me, but I couldnt get past the idea of spending six months trapped in a smelly enclosure while eating freeze-dried lasagna, bathing with a washcloth and breathing recirculated air. Besides, I cared about Earth, not space.

At the Jet Propulsion Laboratory (JPL) in Southern California, where I was based, those who worked on Mars science and those who worked on Earth science competed for attention and praise from management. During regular meetings, Mars People sat in the choice seats nearest the director, who saw Mars as exciting and prestigious and treated the Earth People like stepchildren. A Mars rover cost $2.5 billion, whereas an Earth orbiting satellite was around $400 million. Mars People snubbed Earth People.

I remember when the Deputy Director of Communication lectured me on space exploration as the only way for humanity to move forward. I glanced around his office at the stacks of paper piled across his desk, while he executed his duty to school me on all things NASA. He explained with great confidence how the success of humankind was the result of an innate drive to go and explore, and how the pioneering spirit was integral to human nature. His opinions echoed those of Neil deGrasse Tyson, with whom Id once argued. Tyson and I spent an hour going at it so intensely that I ended up apologizing for accidentally spitting on him. Go ahead and lean in, he told me. Im a New Yorker; I can handle it.

Both Tyson and the NASA director claimed that sending humans to Mars was the best way to excite people about science. They painted a romanticized ideal, with charismatic explorers sailing forth toward wonder and travel and discovery. But to me, exploration represented machismo and pillaging and conquest. In school, we were taught to regard imperialistic conquerors as heroes, even though each journey to discovery was mired in colonial exploitation driven by expansionism. Excerpts from diaries and letters written by Christopher Columbus included descriptions of genocide, slavery and rape. The British explorer, James Cook, committed massacres and kidnapped Native people. Such atrocities were not humanity.

These space enthusiasts also claimed that during NASAs Apollo Program (1963-1972), the American public was more scientifically literate, which was a talking point supporting space flight to Mars. But there was no empirical evidence for the assertion that human or robotic space-travel increased public interest in science. Science literacy among US adults hasnt changed for decades. So why would dredging it up again move society now? If space travel were so inspirational, then more people would be able to name astronauts other than Buzz Aldrin or Neil Armstrong. They cant.

True, many Americans have an abysmal understanding of how the world works. According to the Pew Research Center, 33 percent of Americans reject the concept of evolution and believe the Earth is less than 10,000 years old. This lack of awareness about how science impacts politics, policy and our future is a problem with economic and civic consequences. We live on this planet together, so our collective actions impact each other as well as other species. Every apathetic citizen or hostile denier represents a gamble on everyone elses future.

The coronavirus started as an ecological pandemic. It spread quickly because of globalization and public misunderstanding of, and distrust in, science. Instead of trips to Mars, we could focus attention on Earth and clean up the mess here before exploring new horizons.

During the 13 years I taught college-level oceanography, my students told me they believed science was cold and difficult to understand. But these young people were keen to learn about Earths climate and get involved. I convinced them that literacy involved connections they made to the world, not facts to memorize.

After Trump took office, I was called into JPL Ethics and told that climate change was a sensitive topic, and that my work was being monitored. By September 2017, Id been censored, intimidated by Media Relations, stripped of my duties and barred from speaking to the press. My manager suggested I write something about Mars.

I knew NASA administrators cared about Mars. Neil deGrasse Tyson cared about Mars. But I didnt, and neither did many of my friends and neighbors. My responsibility to be honest about climate change outweighed my responsibility to protect NASA. I refused to stay quiet. By October, I was forced out.

Was it worth it? Yes. Our generations ambitious project, our moonshot, isnt space travel. Its the climate crisis, plastic pollution and public health.

Our scientific talents should be focused here. On Earth.

See the original post:

I worked for a decade at NASA and I can tell you the 'Mars bros' have it all wrong - The Independent

Fast 9 star might have revealed that the movie goes to space – Digital Spy

Fast & Furious 9 star Ludacris has potentially given away that the franchise is about to head into space.

The idea that space was the final frontier for the Fast franchise has been a long-running joke, but given how outlandish the series has become, we wouldn't be too surprised.

Appearing on Sirius XM's The Jess Cagle Show, Ludacris explained how the delay on the release of Fast 9 has given the creative minds behind the franchise more time to make the film (and possible sequels) some of the best of all time.

Prince Williams / ContributorGetty Images

Co-host Julia Cunningham then said: "I don't even know creatively what they could come up with to wow us even though I know they do every time.

"I'm like, space has to be involved, submarines, I don't even know. In my mind I can't imagine what happens in the next movie."

Ludacris responded: "You just said something very important. I will say that you are very intuitive, cause you said something right, but I'm not going to give it away."

"It was space I said space," Julia then shouted, to which the rapper simply put his hand over his mouth, so as not to say anything more.

Related: Vin Diesel hints there's a "big surprise" coming for Fast & Furious 9

Obviously, this could all be a big wind up, but we're actually kind of excited about the possibility of seeing the gang potentially hop in a spaceship.

Last year, Fast & Furious screenwriter Chris Morgan admitted that "nothings out of the question" when asked whether we could see Dominic Toretto and the gang travel to space one day.

"It just has to be cool and it has to be good," he explained in an interview with Polygon. "You know, thats the thing. I would say nothing is off-limits as long as we can stay on the right side of keeping the audience engaged."

Fast & Furious 9 will be released in April 2021.

Fast & Furious 8-Film Collection DVD (1-8 Box Set) [2017]

24.99

Fast & Furious 8 (Amazon Prime)

amazon.co.uk

Fast & Furious 7 [Blu-ray] [2017] [Region Free]

3.44

Fast & Furious 6 (Limited Edition Steelbook) [Blu-ray] [2013] [Region Free]

6.50

Fast & Furious 1-6 (includes sneak peek of Fast & Furious 7) [Blu-ray] [2015]

Universal Picturesamazon.co.uk

Fast & Furious 5 [DVD] [2011]

Universal Picturesamazon.co.uk

Fast & Furious 1-8 (4K + Blu-ray) [2019] [Region Free]

Fast & Furious Monopoly Board Game

23.71

Digital Spy now has a newsletter sign up to get it sent straight to your inbox.

Want up-to-the-minute entertainment news and features? Just hit 'Like' on our Digital Spy Facebook page and 'Follow' on our @digitalspy Instagram and Twitter accounts.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

Continued here:

Fast 9 star might have revealed that the movie goes to space - Digital Spy

Stocks making the biggest moves after hours: Virgin Galactic, Redfin, Carnival and more – CNBC

A Redfin Corp. 'For Sale' sign stands outside of a home in Seattle, Washington.

David Ryder | Bloomberg | Getty Images

Check out the companies making headlines after the bell:

Marathon Oil The oil company's stock climbed 1% in extended trading after falling 7.05% earlier Thursday. Oil dropped 3%during the day amid concerns over rising coronavirus case counts.

Redfin Shares of the real estate brokerage fell 2% after the closing bell. The company's stock hit an all-time high earlier in the week as real estate recovers from pandemic-forced lockdowns across the country. The pandemic is causing an exodus from cities and home searches are now increasingly in the suburbs, Ryan Schneider, chief executive ofRealogy Holdings, told CNBC Thursday.

Virgin GalacticShares of the space travel company rose 1% in extended trading after the stock jumped nearly 16% earlier in the day. Last week, Virgin Galactic said it expects to attain its Federal Aviation Administration license within the next two spaceflights, which would bring the company closer to flying customers.

Bed Bath & Beyond Shares of thehome goods retailer climbed 1% in extended trading after falling 24.5% in regular hours. Bed Bath & Beyond released its first-quarter financial results Wednesday and said it will close about 200 stores over the next two years.

NIO The Chinese electric-car maker's stock rose 2% after the market closed. Shares jumped 13% during the day, continuing an upward trend for the stock. Last week Nio reported a monthly record of 3,740 vehicle deliveries for June and said it delivered 10,331 vehicles in the second quarter.

Carnival The cruise operator's stock climbed 1% in extended trading. Earlier Thursday, Carnival's subsidiary AIDA Cruises announced it would restart vacation trips in August.

View post:

Stocks making the biggest moves after hours: Virgin Galactic, Redfin, Carnival and more - CNBC

An End to Empty Seats on Canadas Airlines – The New York Times

Photos of empty airports have come to symbolize the head-spinning drop in air travel during the pandemic. But the more surprising illustration for me involves a now-crowded space.

The parking lots of rental car agencies near the Ottawa airport are now overstuffed with unwanted cars. So many of them have piled up since air travel has fallen by 90 percent in Canada that the unwanted rentals have overflowed into the vast parking lot of a nearby convention center.

Recently, Canadas two major airlines, Air Canada and WestJet, have been pushing to get more people back on their planes, urging politicians to substantially ease virus-related restrictions, including expanding border travel with the United States, as they move to restart additional routes later this month.

This is hundreds of times worse than 9/11, SARS, or the global financial crisis quite frankly combined, Calin Rovinescu, the chief executive of Air Canada, told the Financial Post in an interview.

But at the same time that Mr. Rovinescu and his counterparts are working to get more people back in the air, theyve made one change that gives some health officials pause.

On Canada Day, both Air Canada and WestJet ended what the industry calls seat blocking, leaving a vacant seat between passengers. Though that gap was far short of the minimum recommended distance of 2 meters, it was still a gap.

So while health officials are urging Canadians to keep their distance as various measures are eased, airlines are putting them in close contact in an enclosed space for flights that can last hours.

During recent testimony before the House of Commons health committee, officials from all of Canadas major airlines played down the need to keep passengers apart and emphasized what they called a cascading or multilayered approach to making sure infections dont spread aboard flights. That approach, they repeatedly said, includes taking into account the quality of the air filtration systems on planes.

In an email, Air Canada explained the end of seat blocking to me this way: While we would all like a single measure that reduces risk, we are left to use a combination of approaches to mitigate risk as far as practical.

It added: It is very important that people understand how efficiently aircraft ventilation works to refresh air regularly onboard every 2 to 3 minutes, which is a key reason there has been no reports of disease outbreak clusters onboard flights.

But scientists, public health authorities and physicians seem less enthusiastic about a return to jampacked cabins and, for that matter, about moving large numbers of people around the country.

From a public health perspective the physical distancing is one of the key public health measures, Dr. Howard Njoo, the deputy chief public health officer of Canada, said at a news conference when asked about the airlines new plan. Physical distancing is our recommendation.

Dr. David N. Fisman, an epidemiologist at the University of Torontos Dalla Lana School of Public Health, agreed that having multiple measures can lead to greater overall control of infections and he added that hes been surprised by the lack of outbreaks clustered around flights.

That said, at the end of the day, proximity and crowding are important factors in facilitating disease transmission, so maintaining as much space as possible between individuals and requiring masks when space cant be maintained seems quite common-sensical to me, he said. I cant imagine that airplanes have some magical property that makes droplet borne transmission difficult if people are packed closely together.

Dr. Cory Neudorf a professor at the University of Saskatchewans medical school and the medical director for health surveillance at Saskatchewan Health Authority, told me in an email that viruses can still pass between passengers even with the most vigorous filtration.

Airplanes try to mitigate this through frequent air circulation and use of HEPA filters, but yes, you can still be infected if you breathe in the particles on their way to the filters, he wrote in the email.

He added that limiting the number of people aboard planes cuts the risk of transmission in other ways.

Fewer people in a given shared space means fewer people touching shared surfaces, so risk is reduced, especially if you dont have someone using the same arm rest or other surfaces as they walk down aisles, use the washroom etc., he wrote.

Air Canada will allow economy class passengers on flights that are nearly full to rebook at no cost. That, of course, assumes travel flexibility and the availability of flights with lots of empty seats.

Moris Moreno recently produced a record for The Times of air travel from Seattle to Boston with his family, although the middle seats were empty when he took to the skies.

Balarama Holness is a Montreal educator, broadcaster, law student, former professional Canadian football player, and one of the leaders of Canadas current Black rights and anti-racism movement. He told Dan Bilefsky he aspires to be a Canadian Obama.

Justin Trudeau is at the center of another conflict-of-interest investigation his third since he became Prime Minister in 2015. This one is over his familys connections to the international WE Charity, which his government had awarded a no-bid contract to disburse hundreds of millions of dollars in aid to student volunteers. This week, it was revealed that Mr. Trudeaus mother and brother were paid more than 280,000 Canadian dollars over four years by the charity for speaking at its events.

For those feeling stir-crazy under coronavirus travel restrictions, you can travel virtually along the 360-mile Tshiuetin railroad in rural Quebec, from Sept-les to Schefferville. Partly owned and wholly operated by the three First Nations that it connects, the line is a symbol of reclamation and defiance for those it serves, writes Chlo Ellingson. Her photos are wonderful.

A native of Windsor, Ontario, Ian Austen was educated in Toronto, lives in Ottawa and has reported about Canada for The New York Times for the past 16 years. Follow him on Twitter at @ianrausten.

Were eager to have your thoughts about this newsletter and events in Canada in general. Please send them to nytcanada@nytimes.com.

Forward it to your friends, and let them know they can sign up here.

Continue reading here:

An End to Empty Seats on Canadas Airlines - The New York Times

Economy shouldn’t have to rely on charity from billionaires, says Biden backer Pete Buttigieg – CNBC

The United States should not have to rely as much on charitable contributions from billionaires to help solve the nation's economic challenges,Biden campaign surrogate Pete Buttigieg told CNBC on Thursday.

"It's wonderful when there are these major commitments, generous commitments by individuals, but we've also got to ask how things got so unequal in the first place," the former Democratic presidential candidate said on "Squawk Box."

Buttigieg's remarks came in response to a question about whether to tax charitablecontributions such as the one that multibillionaire Warren Buffettjust announced. The "Oracle of Omaha" on Wednesday saidhe woulddonate nearly $3 billion worth ofBerkshire Hathawaystock.As of Wednesday's market close, Buffett ranked No. 4 on Forbes' list of the richest people in the world with an estimated net-worth of $67.6 billion.

Buffett has said he will give away nearly all of his fortune, with most of it going to a handful of philanthropic organizations including the Bill and Melinda Gates Foundation and charities run by his three children.Since 2006, he has donated more than $37 billion, including the latest contribution.

Instead of taxing philanthropy, Buttigieg said it would make more sense for the U.S. to have a more equitable tax structure on the "front end." That way, he said, the tax revenue wouldsupport programs and other efforts that reduce inequality that have more input from voters.

"If a little bit more of that was making its way into a democratically guided process, in other words the kind of research and development that invent trillion dollar ideas like the internet itself and space travel, we know our country is better off," said Buttigieg,the former two-term mayor of South Bend, Indiana. "We've got to ask where the balance is."

For example, Buttigieg referenced a report last year that found a full-time worker earning the federal minimum wage of $7.25 per hour is unable to pay for an affordable two-bedroom apartment anywhere in the U.S. However, some states and localities have higher minimum wages than the federal rate, which has remained the same forabouta decade.

"I would argue that if that weren't the case, if we had higher wages and more public investment, we wouldn't need to lean on philanthropy quite as much as we do," Buttigieg said.

Buttigieg, who won the most delegates in February's Iowa caucus and finished second in the New Hampshire primary, ended his unlikely presidential bid on March 1, one day after Joe Biden's crucial victory in South Carolina.

Buttigiegendorsed the former vice president shortly after leaving the race.

On Thursday, Biden released an economic plan that proposes investments in American manufacturing. It calls for a $400 billion, four-year increase in government purchasing of U.S.-based goods and services, along with another $300 billion on research and development in technology.The Biden plan also touts the candidate's long-standing promises to strengthen workers' collective bargaining rights and to roll back part of the tax cuts passed by President Donald Trump.

Buttigieg said the U.S. economy needs that kind of spending to help it recover from the impact of the coronavirus crisis, which has put millions of American residents out of work. While saying he's attentive to concerns about government deficits, Buttigieg said investment plans like Biden'shave shown to have a "much higher rate of return than tax cuts."

"If you look at the overall picture of where our economy is headed, we don't have a choice and we can handle these kinds of investments if we make them before it's too late," Buttigieg said.

Continued here:

Economy shouldn't have to rely on charity from billionaires, says Biden backer Pete Buttigieg - CNBC

How many ETs are in our galaxy? Ask the Alien Civilization Calculator – EarthSky

A long-exposure photograph of the Milky Way overlaid by the Drake equation: an equation developed by Frank Drake in 1961 for estimating the number of extraterrestrial civilizations in the galaxy. Image via Medium.com.

Are we alone in our galaxy? If not, how many other civilizations might there be? And where are they? In 1961, astronomer Frank Drake created whats now known as the Drake Equation shown above a tool for discussing the question of alien life. Now two scientists have incorporated the Drake Equation into a new system called the Alien Civilization Calculator. In addition to the Drake Equation, the new calculator also employs a new method called the Astrobiological Copernican Limits, to find the number of advanced civilizations we might be able to communicate with in the future. Like the Drake Equation itself, the new calculator is a tool for thinking and discussing. Its an aid for contemplating how many advanced alien civilizations there might be theoretically speaking in our own galaxy. Using the calculator, you can compare outcomes using the Drake Equation and the Astrobiological Copernican Limits. And you can adjust the input values, to how different factors might affect the number of alien civilizations in our Milky Way galaxy, and how close the nearest ones might be.

The scientists who created the Alien Civilization Calculator are with Omni Calculator which has many different types of calculators under one roof (1,197 according to the website) and which, Omni Calculator says, makes it:

super simple for anyone to solve their day-to-day calculations and math problems with ease in no time.

So a super simple answer to the question of alien life? Lets see.

A young Frank Drake. Drake, an astronomer, has been a leader in the search for extraterrestrial intelligence since the 1960s when he implemented Project Ozma to search for radio signals from advanced extraterrestrial civilizations. He developed the Drake equation. And he created the Arecibo Message, a 1974 interstellar radio message from Earth to the globular star cluster M13, carrying encoded information about Earth and its humans. Image via Spaceflight Now.

The inspiration for the calculator came from recent news about the Astrobiological Copernican Limits method, a new method for looking at the possibilities for alien life, based on a study by Tom Westby and Christopher J. Conselice. That study reached the conclusion that there should be at least 36 worlds with advanced alien societies in our galaxy. The peer-reviewed paper was published on April 8, 2020, in The Astrophysical Journal. The study estimated that the nearest civilization would probably be about 17,000 light-years away, so not all that close.

This gave Steve Wooding and Dominik Czernia at Omni Calculator the idea to create a new calculator, combining the Astrobiological Copernican Limits method with the Drake Equation. The two approaches are rather different, so using and comparing both of them was a unique and novel way to try to find possible solutions to what scientists called the Fermi Paradox. That paradox is based on physicist Enrico Fermis famous pondering about an apparent contradiction. That is, the Drake equation suggests there should be many, many extraterrestrial civilizations. Yet, all rumors to the contrary aside, theres been no hard and fast evidence for these civilizations that we all can see and agree upon. Fermi famously asked:

Where are they?

Enrico Fermi (1901-1954) was an Italian-American physicist, who received a 1938 Nobel Prize in physics for his work in nuclear physics. He famously asked, Where are they? Image via Wikimedia Commons.

Using the calculator is quite simple. First, you select which method you want to use, and then fill in all the fields in the Milky Way assumptions section. The result gives you an estimate of the number of civilizations in the galaxy, depending on the variables that you input, such as star formation rate, number of stars with planets, etc. It will also tell you how far away the closest of those civilizations should be. You can create many different combinations of variables to test your ideas out with. Theres even a space travel calculator to find out how long it would take to travel to these other worlds by rocket!

So how do the two methods compare?

The first, the Drake Equation, is a rather simple formula, and was developed by astronomer Frank Drake, who is also the father of modern SETI, the Search for Extraterrestrial Intelligence. The formula looks like this:

N = R* x fp x ne x fl x fs x ft x L

N stands for the number of detectable civilizations. The other variables are as follows:

R* is the average rate of star formation in our galaxy. By observing our galaxy and all nearby galaxies, we know its about 2.3 per year;fp is the percentage of stars that have at least one planet. Scientists agree that almost every star has a planet, therefore fp ? 100%;ne is the average number of hospitable planets per star. Thanks to the Kepler space mission, we know that each star in the galaxy has, on average, four Earth-sized planets;fl is the percentage of those planets where life actually emerges;fs is the percentage of those planets where life evolves into intelligent beings;ft is the percentage of those planets with intelligent creatures capable of interstellar communication; andL is the lifetime a civilization remains detectable for.

Perhaps the worlds ongoing effort to search for extraterrestrial life operates under the auspices of Yuri Milners project called Breakthrough Listen. Here is the Green Bank Telescope in West Virginia, one of the telescopes used by Breakthrough Listen for SETI. This is an artists concept of a signal from a Fast Radio Burst or FRB detected by the telescope. FRBs are one of the sorts of objects on the new Breakthrough Listen Exotica list, which some hope will help guide the search for ET. Image via UC Berkeley.

The first three are now well-known or fairly well-known at this point, but the remaining three are not. This of course makes it difficult still to come to any solid conclusions. But the Drake Equation is what has been used by astronomers for decades now, to try to come to at least some kind of understanding of how common, or rare, intelligent life might be.

Thats where the second method, the Astrobiological Copernican Limits, comes into play. Westby and Conselice developed it in April 2020 as a more modern form of the Drake Equation. The parameters are different from the Drake Equation, and based on the assumption that any habitable, Earth-like planet, presumably near in size to the Earth, with a similar composition, atmosphere and water, would eventually host life. That may sound like a big assumption to make, and it is. This method is also based on the one example we have so far of a communicating, intelligent civilization, our own.The paper has generated a lot of discussion, including criticism from some fellow scientists. For example, Caleb Scharf, Director of Astrobiology at Columbia University, wrote on Twitter:

From the paper:

We present a cosmic perspective on the search for life and examine the likely number of Communicating Extra-Terrestrial Intelligent civilizations (CETI) in our galaxy by utilizing the latest astrophysical information. Our calculation involves Galactic star-formation histories, metallicity distributions, and the likelihood of stars hosting Earth-like planets in habitable zones, under specific assumptions which we describe as the Astrobiological Copernican Weak and Strong conditions. These assumptions are based on the one situation in which intelligent, communicative life is known to exist, on our own planet.

For the purposes of the calculator, the premise is that an Earth-like planet could only support intelligent life when it is five billion years old or older. This is based on the knowledge that Earth is about five billion years old, and humanity has only appeared within the last three million years or so, as currently understood. The equation for this method looks like this:

N = N* x fL x fHZ x fM x (L/?)

Giant artificial constructions in space, such as this hypothetical type of Dyson sphere, are one kind of possible technosignature. Image via CapnHack.

Again, N stands for the number of intelligent, and communicable, civilizations. But now the variables are as such:

N* is the total number of stars within the galaxy;fL is the percentage of those stars which are at least 5 billion years old;fHZ is the percentage of those stars which host a suitable planet for supporting life;fM is the percentage of those stars for which there is a sufficient amount of metal resources allowing the formation of advanced biology and a communicable civilization;L is the average lifetime of an advanced, communicable civilization; and? is the average amount of time available for life to develop on a planet, or, in other words, ? is the time in which life could exist.

For this model, users can also choose between strong, moderate or weak values in regards to how strict conditions are for intelligent life to appear and evolve. Strong = only a few stars with planets able to host such life, while weak = many such stars.

The maximum distance results from both methods can be used to calculate how many civilizations might be nearby. As might be expected, the farther out you go, the greater the chances of a habitable planet having intelligent life. This is based on the volume of space involved and simple statistics. For example, according to the calculator, there is only a one in 3 billion chance of the nearest star, the Alpha Centauri system, having a planet with intelligent life. But the farther out you go, the greater the odds.

As discussed in EarthSky recently, we are also now getting a better idea of where to search for evidence of advanced alien civilizations. The new Exotica Catalog, aka The Breakthrough Listen Exotic Target Catalog, from Breakthrough Listen, currently lists over 700 objects and phenomena of interest in the universe that might be good places to look. The catalog lists one of everything in the known universe that might be a good target for study and observations.

Steven Wooding and Dominik Czernia of Omni Calculator, who created the Alien Civilization Calculator. Image via Omni Calculator.

The catalog will help guide the search efforts of those looking for evidence of intelligent life, in particular by searching for technosignatures artifacts or phenomena produced by a highly advanced intelligent species that could be detected by telescopes. Modern SETI, the Search for Extraterrestrial Intelligence, is now finally starting to move beyond just looking for alien radio signals. Technosignatures could include many different possibilities, like Dyson spheres built around stars or other huge artificial constructions, lasers or other more exotic communications like Fast Radio Bursts, evidence of industrial pollution on a planet, etc.

The Alien Civilization Calculator is useful in trying to determine how many civilizations might exist in our galaxy, albeit based on many variables, and how close by some of them might be. Projects like the Exotic Catalog and Breakthrough Listen/ SETI will help to narrow down more specific locations and actual detected candidates. This kind of multi-pronged approach is what is needed, even if it still takes a long time to actually find something or someone.

The famous Drake Equation in illustrative form, depicting the different variables involved. The new calculator combines this formula with the new Astrobiological Copernican Limits method. Image via SETI Institute/ Enter the Realm of Guy Erma.

Bottom line: The new Alien Civilization Calculator combines two different methods of calculating how many advanced alien civilizations may exist in our galaxy.

Via Alien Civilization Calculator

See the original post here:

How many ETs are in our galaxy? Ask the Alien Civilization Calculator - EarthSky

COVID-19 Pandemic Amplifies Growth Opportunities in the Ultrathin and Superlight Solar Cells Market till 2023, TMR Research Report – Jewish Life News

Global Ultrathin and Superlight Solar Cells Market

Solar power is already a major part of the global renewable energy mix. The low production cost of solar energy, the abundant availability of solar power across the world, and the ease of use of solar power generation systems have led to the widespread usage of solar energy for both residential and nonresidential uses. Several countries in developed as well as developing regions have encouraged the widespread utilization of solar power to ease the pressure on the countries main power grids. Tax incentives and government entry into the field of renewable power have become commonplace all over the world, as solar photovoltaic has become a major energy source in many regions.

The firm foothold already established by the solar power sector in the overall energy generation field will massively help the development of ultrathin and superlight solar cells in the coming years. Whereas solar power is already an established renewable energy source in many countries, the application spectrum of the same is widening in several regions, which is expected to be greatly helped by the innovation of ultrathin and superlight solar cells.

The report helps deliver precise facts about the global ultrathin and superlight solar cells market by using a granular approach. Major regional segments of the global ultrathin and superlight solar cells market are examined in the report in order to provide a clear view of the geographical breakdown of the market. The competitive landscape of the market is also examined to provide key insights to readers.

Request for Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10550

Global Ultrathin and Superlight Solar Cells Market: Drivers and Restraints

Recently, scientists at MIT developed a solar cell literally thinner than human hair. Such ultrathin and superlight solar cells it only weighs around 3.6 g/square meter are the order of the day, and the proof of concept developed by MIT researchers will help drive the global ultrathin and superlight solar cells market massively. While the actual model developed by MIT scientists is too small and lightweight for practical use, since it would be blown away by the slightest of breezes, the field of ultrathin and superlight solar cells is just getting started. The application of ultrathin and superlight solar cells includes, but is not limited to, space travel and high-altitude balloons, where the weight-to-output ratio of energy systems can be a deciding factor. Such solar cells could even become part of apparel and wearable devices without the customer ever realizing it, potentially completely transforming the wearable electronics industry.

Request for Covid-19 Impact Analysis @ https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=10550

The wide-ranging potential application spectrum of ultrathin and superlight solar cells will be a major driver for the global market, since R&D in the field has been allowed to go on unhindered in many regions. The high weight-to-output ratio of ultrathin and superlight solar cells MITs design delivers 400 times more energy per weight than conventional silicon-based solar cells means that widespread usage of the cells is beneficial for alleviating the rising dependence on fossil fuels, which has helped the market garner government support.

The major restraint on the global ultrathin and superlight solar cells market is the difficulty in expanding the scale of the operation of the industry. While initial R&D in ultrathin and superlight solar cells has been promising, scaling up to commercial production will require significant cost reductions for the technology to be feasible on a large scale. The sophisticated technology required to manufacture ultrathin and superlight solar cells is currently not available across the world, with developed regions such as North America dominating the R&D scenario. However, these constraints could be eased by steady demand in fields where price is no factor, such as space exploration and defense.

For More Info View @https://www.transparencymarketresearch.com/casestudies/food-and-beverages-case-study

Excerpt from:

COVID-19 Pandemic Amplifies Growth Opportunities in the Ultrathin and Superlight Solar Cells Market till 2023, TMR Research Report - Jewish Life News

The Euclid space telescope is coming together – Space Daily

ESA's Euclid mission has reached another milestone on its journey towards launch. Its two instruments are now built and fully tested. These have been delivered to Airbus Defence and Space in Toulouse, France, where they are now being integrated with the telescope to form the mission's payload module.

Euclid consists of a 1.2-metre mirror telescope that is designed to work at both visible and near-infrared wavelengths - the latter being just longer than the red light humans can see. The telescope will collect light from distant cosmic objects and feed it into two instruments.

The Visible instrument (VIS) and the Near Infrared Spectrometer and Photometer (NISP) will run in parallel, recording data simultaneously from whatever portion of the sky the telescope is pointed at.

Euclid's mission is to measure the shapes of more than a billion galaxies, and the accurate redshifts of tens of millions of galaxies across more than one third of the sky. The redshift is an effect caused by the expansion of the Universe. It stretches the wavelength of light emitted by distant galaxies; the further away the galaxy, the more extreme its redshift. The galaxies in Euclid's survey will span 10 billion years of cosmic history, and allow scientists to investigate the mysterious dark matter and dark energy that are thought to dominate the Universe.

The VIS instrument will handle the precise measurement of galaxy shapes by taking the very best images of distant galaxies that it possibly can. To do this, the instrument uses a mosaic of 36 CCDs, each of which contains 4000 pixels by 4000 pixels. This gives the detector a total of about 600 megapixels.

"The design, development, manufacturing, testing and calibration of the VIS instrument over a dozen years to a stringent specification has been a challenge," says Mark Cropper, VIS instrument Lead and Professor at the UCL Mullard Space Science Laboratory, UK.

"We are immensely proud of what the VIS Team has achieved to bring this project to its culmination. That the final performance exceeds our expectations is a tribute to their expertise, dedication and professionalism."

Not only is the number of pixels impressive, the instrument will also deliver the best low-light sensitivity over a broad range of wavelengths at long integration times.

"These are very special CCDs, they've been developed specifically for Euclid over many years," says Alex Short, ESA's VIS payload engineer.

The other instrument, NISP, is dedicated to making spectroscopic measurements of galaxies, which involves splitting their light into individual wavelengths. This allows the redshifts to be deduced. This property allows cosmologists to estimate the distance to the galaxy in question, and will allow Euclid's data to be turned into the largest, most accurate 3D survey of the Universe ever conducted.

"The international NISP team and supporting industries made an incredible job to design, develop and test this challenging instrument," says Thierry Maciaszek, NISP instrument project manager, from CNES and Laboratoire d'Astrophysique de Marseille, France.

"This is, however, not the end of the story for us as many major activities have to be completed with NISP at satellite level. We are waiting impatiently for the first light in flight demonstrating the excellent global performances."

The NISP detector will feature the largest field of view ever flown in space for an infrared instrument.

"The quality of the optics is just amazing," says Tobias Boenke, Mission System and NISP Instrument Engineer at ESA.

A key factor in achieving Euclid's exceptional optical accuracy was a decision made early in the project's history to construct the entire payload module out of silicon carbide. The use of this material at ESA was pioneered in the manufacture of the telescope for the Herschel space mission. On ESA's Gaia mission, the support structure for the spacecraft's subsystems were mounted on a silicon carbide frame. On Euclid, the material has been used for the instruments as well as the telescope.

Whereas metal expands and contracts as its temperature changes, thus degrading an optical system's ability to focus light, silicon carbide is extremely stable to such variations in temperature. But using the compound brings its own challenges. Silicon carbide is a ceramic and so much more brittle than metal.

"It was a big challenge to be able to manufacture the instruments from this material and make sure they can remain undamaged during the launch," adds Tobias.

Like VIS, NISP also uses specially designed state-of-the-art detectors to record the faint light coming from distant stars and galaxies. Unlike VIS, NISP can also operate in spectrographic mode. The detectors, which are operated at -180 C to provide ultra-low noise and high sensitivity, register these 'spectra' and convert them into tiny electronic signals. These signals can then be amplified and accurately measured to provide the photometric and spectroscopic redshifts.

The instruments will receive light from Euclid's telescope, which has already been assembled at Airbus, Toulouse. Like the instruments, it too is made from silicon carbide and is a state-of-the art construction in all senses.

"We are pushing all the manufacturing levels to the limit," says Luis Miguel Gaspar Venancio, ESA's Mission Performance and Optical Systems Engineer.

A special component behind the telescope, called the dichroic, separates the collected light and diverts the visible wavelengths to VIS and the infrared wavelengths to NISP.

When the information from VIS and NISP is combined, scientists will be able to deduce the way that the Universe's large-scale distribution of galactic structures has built up throughout cosmic history. This will help them determine the speed at which such structures grow, providing strong constraints on the nature and amount of dark matter and dark energy in the Universe.

The instruments were prepared for delivery to Airbus just before the COVID-19 pandemic imposed restrictions and lockdowns in many ESA member states. Fortunately, VIS was already at Airbus, and NISP had to wait for a few weeks for shipment from Marseille to Toulouse, but was not on the critical path.

"I am extremely grateful to all project parties: institutes, industry and colleagues at ESA for their dedication and commitment during these difficult times," says Giuseppe Racca, ESA's Euclid project manager.

"We were hit by the pandemic in a particularly critical moment when both VIS and NISP were to be transferred to industry. Despite the work and travel restrictions a concerted effort by all parties allowed to minimise the delays by implementing distributed and sequential integration activities of the instrument units and remote monitoring."

Now that the instruments have been delivered to Airbus, they will be integrated first with the telescope, and next with the rest of the payload module. It has been a long journey getting this far. Euclid was selected for implementation in 2011, having already undergone almost five years of studies. While there is still a lot of hard work and testing ahead, the delivery of the instruments and telescope means that the spacecraft can really begin to come together.

"Finally, we have something in front of our eyes," says Luis Miguel. "It's not just paper anymore. It's a fantastic piece of hardware; beautiful in a way."

Integrating the payload module will last several months as it is painstaking work to get everything bolted together, precisely aligned and electronically talking. The instrument's control units have already been mechanically and electrically integrated to the payload module. These tests have verified that the instruments can be properly powered by the spacecraft, can talk to the onboard computers, and can transmit the science data that will then be downloaded to ground through the spacecraft antennas.

Once the telescope has been integrated with the rest of the payload module, it will be shipped to Centre Spatial de Liege, Belgium, for 'end-to-end' testing in a thermal vacuum chamber that can simulate the conditions of space as well as possible on Earth. This test is scheduled to take place in February and March 2021.

Once that test shows that everything is working as expected, the payload module will be shipped to the prime contractor Thales Alenia Space (TAS), in Torino, Italy. TAS has been building the service module, which contains essential systems such as power, propulsion and communications.

The service module's main structure recently passed its structural and thermal tests and is now ready to have the various systems integrated inside. TAS will begin by laying down the pipelines for the propulsion systems, and the cabling for other distributed systems. Flight electronics, including computers, power units, and attitude control units, are already mounted on their own structural panels and these will now be installed inside the main structure. Integration is due to be complete in the third quarter of the year, at which time tests will be performed.

TAS will then integrate the payload module with the service module to form the final, finished spacecraft. Then, another round of tests will ensure that everything is working together properly. At that point, the spacecraft is essentially finished, and ready for launch.

Launch is currently scheduled for the second half of 2022 from Europe's spaceport, Kourou, French Guiana.

Related LinksEuclid at ESAStellar Chemistry, The Universe And All Within It

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.

Read more:

The Euclid space telescope is coming together - Space Daily